Astellas Pharma, Inc.'s key oncology candidate zolbetuximab has met its primary and secondary endpoints in the Phase III SPOTLIGHT trial in combination with chemotherapy for gastrointestinal cancers, paving the way for a possible approval filing for the first-in-class, claudin (CLDN) 18.2-targeting antibody.
The drug, granted Fast Track Designation by the US Food and Drug Administration (FDA) in August 2022, was assessed in...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

